Patents Examined by Bruce Campell
  • Prion protein binding materials and methods of use
    Patent number: 7510848
    Abstract: Prion protein binding materials and methods for using the binding materials to detect or remove a prion protein from a sample, such as a biological fluid or an environmental sample. The binding materials are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), recombinant prion protein (PrPr), and proteinase resistant prion protein (PrPres). Prions from various species, including humans and hamsters, are bound by the binding materials.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: March 31, 2009
    Assignees: North Carolina State University, Pathogen Removal and Diagnostic Technologies Inc.
    Inventors: David J. Hammond, Ruben G. Carbonell, Honglue Shen, Patrick V. Gurgel, Viterose Wiltshire-Lyerly, Steven J. Burton
  • Expression vectors and uses thereof
    Patent number: 7510718
    Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing the vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of the vectors. The novel vectors comprise (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. The vectors lack a papilloma virus origin of replication.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: March 31, 2009
    Assignee: Fit Biotech Oyj PLC
    Inventors: Kai Krohn, Vesna Blazevic, Marja Tahtinen, Mart Ustav, Urve Toots, Andres Mannik, Annamari Ranki, Ene Ustav
  • Methods for producing purified adenoviral vectors
    Patent number: 7510875
    Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: March 31, 2009
    Assignee: Introgen Therapuetics, Inc.
    Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Deborah Wilson, Lucetta Caston
  • Protozoan derived compositions and methods of use thereof
    Patent number: 7510715
    Abstract: The instant invention relates to methods for treating a subject suffering from or susceptible to an autoimmune disease or disorder, or a disease or disorder having an autoimmune component, comprising administering to the subject an effective amount of cyclophilin or a biologically active fragment thereof.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: March 31, 2009
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Julio Aliberti, John Andersen, Hana Golding, Alan Sher
  • Methods of producing influenza vaccine compositions
    Patent number: 7510719
    Abstract: Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: March 31, 2009
    Assignee: MedImmune, LLC
    Inventors: Qi Dang, Richard Schwartz
  • Anti hepatitis C virus antibody and uses thereof
    Patent number: 7507408
    Abstract: Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: March 24, 2009
    Assignee: Genmab A/S
    Inventors: Christian Reiter, Francois Habersetzer, Anne Fournillier, Christian Trepo, Claude Desgranges, Genevieve Inchauspe
  • Single-chain antibody acting against 37 kDa/67 kDa Iaminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof
    Patent number: 7507797
    Abstract: Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: March 24, 2009
    Assignee: Affimed Therapeutics AG
    Inventors: Stefan Knackmuss, Clémence Rey, Peter Röttgen, Claudia Büttner, Uwe Reusch
  • Attenuated influenza NS1 variants
    Patent number: 7507411
    Abstract: Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating an immune response against influenza virus, methods of interfering with influenza virus replication, and methods of treating and preventing influenza virus infection are described.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: March 24, 2009
    Assignee: University of Saskatchewan
    Inventors: Yan Zhou, Yeun-Kyung Shin, Lorne A. Babiuk, Qiang Liu
  • Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
    Patent number: 7507418
    Abstract: Infection with obesifying adenoviruses in animals and humans may be used to predict changes in body weight and disease status. More particularly, infection with certain adenoviruses, such as adenovirus type 36 (Ad-36) and adenovirus type 37 (Ad-37) may cause removal of the normal equilibrium factors that control fat cell metabolism and may make individuals more responsive than normal individuals to perturbations, which cause body composition change including weight gain or weight loss.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: March 24, 2009
    Assignee: Obetech, LLC
    Inventors: Richard L. Atkinson, Nikhil V. Dhurandhar
  • Optimized multi-epitope constructs and uses thereof
    Patent number: 7507803
    Abstract: The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: March 24, 2009
    Assignee: Genimmune N.V.
    Inventors: Alessandro Sette, Robert Chesnut, Mark J. Newman, Brian D. Livingston, Lilia Maria Babe, Yiyou Chen, Lawrence M. Deyoung, Manley T. F. Huang, Scott D. Power
  • Detection of human immunodeficiency virus
    Patent number: 7507527
    Abstract: The invention relates to a method of detecting a HIV-infected cell in a mammal. The method includes detecting an HIV 2-LTR circle DNA molecule obtained from a cell of an HIV-positive mammal, especially an HIV-1-positive human.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: March 24, 2009
    Assignee: University of Massachusetts
    Inventor: Mario Stevenson
  • bacteriophage and uses thereof
    Patent number: 7507571
    Abstract: The present invention is directed to isolated Listeria monocytogenes bacteriophage, and methods of using Listeria monocytogenes bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Listeria monocytogenes. The present invention also contemplates the use of Listeria monocytogenes bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Listeria monocytogenes.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: March 24, 2009
    Assignee: Intralytix, Inc.
    Inventors: Gary R. Pasternack, Alexander Sulakvelidze
  • Compositions and methods for generation of infectious hepatitis C virus in immortalized human hepatocytes
    Patent number: 7504255
    Abstract: The present invention provides a cell line capable producing infectious hepatitis C virus 1a (HCV 1a) particles in culture. Disclosed are compositions and methods for an HCV 1a (clone H77) transfected immortal human hepatocyte (IHH) capable of generating infectious HCV 1a virus particles in culture. Also disclosed are methods of using the cell line, or HCV 1a virus particles derived from said cell line, to screen for potential therapeutic agents which interfere with HCV 1a virus propagation to treat hepatic disease.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: March 17, 2009
    Assignee: Saint Louis University
    Inventors: Ratna Ray, Ranjit Ray, Arnab Basu, Tatsuo Kanda
  • Production of viruses viral isolates and vaccines
    Patent number: 7504248
    Abstract: The present invention discloses methods for producing and/or propagating virus particles, such as influenza virus particles, that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle. The invention also provides a method for selective propagation of a set of virus particles, such as influenza virus particles present in an influenza isolate, which have an affinity for receptors comprising a specific glycosylation residue.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: March 17, 2009
    Assignee: Crucell Holland B.V.
    Inventors: Giuseppe Marzio, Maria Grazia Pau, Dirk Jan Elbertus Opstelten, Alphonsus Gerardus Cornelis Maria Uytdehaag
  • Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response
    Patent number: 7504107
    Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: March 17, 2009
    Assignee: MedImmune, LLC
    Inventor: Scott Koenig
  • Vectors comprising guinea pig CMV regulatory elements
    Patent number: 7501129
    Abstract: The invention comprises novel polynucleotides, and related vectors, host cells, methods, and compositions, containing transcriptional enhancers providing very high levels of expression of operably-linked expressible nucleic acid sequences in eukaryotic cells. Advantageously the enhancers may be used in combination with their naturally-associated promoters and/or other genetic elements that increase transcription. The invention comprises eukaryotic expression vectors that are capable of providing increased levels of expression in many cell types over that obtainable from human or murine CMV IE enhancer/promoter elements.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: March 10, 2009
    Assignee: Millipore Corporation
    Inventors: Steven Geraint Williams, Alistair Simpson Irvine, Jonathan Gawn
  • Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
    Patent number: 7501494
    Abstract: This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: March 10, 2009
    Assignee: United Biomedical, Inc.
    Inventors: Shugene Lynn, Chang Yi Wang
  • Immunostimulatory oligonucleotide multimers
    Patent number: 7498426
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: March 3, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Carrier of a diamond fine particle for immobilizing virus
    Patent number: 7498178
    Abstract: The present invention provides a carrier for immobilizing a bio-derived polymer, and especially, the present invention provides a carrier of diamond fine particle for immobilizing a DNA, RNA, protein and peptide, as well as a DNA chip substrate, a carrier for trapping virus and a vaccine. The carrier is prepared by the steps comprising: preparing an initial mixture including a diamond and a non-diamond by means of explosion of a detonating agent; subjecting the initial mixture to an oxidation treatment to obtain a suspension solution including the diamond; and separating a phase including the diamond. According to the present invention, after the oxidation treatment, a basic material having per se volatility or to generate a decomposed material having volatility is added, to neutralize with nitric acid, and thereby obtained diamond fine particle has a functional group on the surface thereof.
    Type: Grant
    Filed: July 13, 2006
    Date of Patent: March 3, 2009
    Inventors: Tadamasa Fujimura, Mituru Akashi, Junji Watanabe, Masato Sone
  • Immunostimulatory oligonucleotide multimers
    Patent number: 7498425
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: March 3, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu